NANOMICRO(688690)2025-04-24 13:40Dividend and Share Repurchase - The proposed cash dividend for 2024 is CNY 0.63 per 10 shares, totaling approximately CNY 25.25 million for the distribution [8]. - The total amount for cash dividends and share repurchases in 2024 is CNY 86.24 million, representing 104.10% of the net profit attributable to shareholders [8]. - The company has implemented a share repurchase amounting to CNY 60.99 million during the year [8]. - The total share capital as of April 23, 2025, is 403,814,765 shares, with 3,066,622 shares held in the repurchase account excluded from the dividend distribution [8]. Financial Performance - The company's operating revenue for 2024 reached RMB 78,245.67 million, representing a 33.33% increase compared to RMB 58,686.51 million in 2023 [26]. - The net profit attributable to shareholders for 2024 was RMB 8,284.34 million, a 20.82% increase from RMB 6,856.63 million in 2023 [26]. - The net profit attributable to shareholders after deducting non-recurring gains and losses surged by 108.55% to RMB 6,587.37 million in 2024 from RMB 3,158.65 million in 2023 [26]. - The net cash flow from operating activities for 2024 was RMB 13,305.52 million, up 5.99% from RMB 12,553.05 million in 2023 [26]. - The total assets at the end of 2024 were RMB 230,959.70 million, an 8.61% increase from RMB 212,656.83 million at the end of 2023 [26]. - The net assets attributable to shareholders increased by 2.64% to RMB 174,842.59 million at the end of 2024 compared to RMB 170,352.79 million at the end of 2023 [26]. Corporate Governance and Audit - The company has received a standard unqualified audit report from Rongcheng Accounting Firm [7]. - The board of directors and supervisory board members have all attended the board meeting, ensuring the report's accuracy and completeness [7]. - The company does not have any special arrangements for corporate governance [10]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties [12]. - The company has not conducted any capital reserve transfers to increase share capital or issued bonus shares for the year [8]. Research and Development - The R&D investment for 2024 was 177 million yuan, up 9.61% from the previous year, accounting for 22.64% of the annual operating revenue [28]. - The company is focusing on the development of new technologies and products in the field of chromatography and separation purification [18]. - The company has developed multiple core technologies in microsphere precision preparation, structural control, surface modification, and large-scale production, which are crucial for various fields including biomedicine and diagnostics [89]. - The company has developed a comprehensive microbead precision preparation technology and is one of the few globally capable of large-scale production of both inorganic and organic high-performance nanomaterials [82]. - The company has achieved large-scale production of monodisperse silica chromatographic fillers with a coefficient of variation (CV) of less than 3% [89]. Market Expansion and Strategy - The company plans to expand its market presence and enhance its product offerings in the biopharmaceutical sector [18]. - The company aims to maintain its growth trajectory and improve operational efficiency in the upcoming fiscal year [18]. - The company is focused on expanding its growth potential by leveraging its foundational technology in microsphere precision preparation [63]. - The company aims to establish an overseas application technology center as part of its strategy to expand into international markets [140]. - The company plans to continue expanding its overseas market presence and integrating its "filler + instrument" marketing teams to enhance customer engagement and service [149]. Product Development and Innovation - The new product NMab Titan has significantly improved capacity performance, enhancing the company's product capabilities in antibody applications [39]. - The company launched new products including 3μm and 1.8μm BioCore Glycan analysis columns, designed for therapeutic protein N-glycan analysis [49]. - The company has introduced a new generation of high-performance nucleic acid affinity products, achieving a 90% increase in binding capacity compared to previous models [104]. - The company has developed high-performance microspheres for optoelectronic display applications, with initial customer integration and small-scale sales achieved [103]. - The company has launched a series of gas chromatographs, including the flagship F80, to meet the demands for intelligent, efficient, and precise performance in scientific analysis [96]. Risks and Challenges - The company faces risks related to the potential failure of new product development and the loss of core technical personnel, which could impact its competitive edge [124]. - The company is facing risks related to the uncertainty of the biopharmaceutical market expansion and potential changes in industry policies [138]. - The rapid growth of the Chinese biopharmaceutical market has intensified competition, with both domestic and international companies increasing their focus on this sector [127]. - The company recognizes the need for a collaborative team approach to succeed in the current competitive environment [197]. Operational Efficiency and Cost Management - The company aims to reduce inventory and accounts receivable as part of its cost reduction and efficiency improvement strategy for 2024 [56]. - The company is committed to improving its credit management policies and inventory management through ERP systems to enhance operational efficiency [133]. - The company plans to optimize production processes to improve the stability of core products and reduce production costs [200]. - The company aims to strengthen cost control and optimize financial operations to ensure stable and sustainable development [200]. Acquisitions and Investments - The company completed the acquisition of Fuli Instruments, enhancing its chromatography technology platform following the acquisition of Saipu Instruments in 2022 [52]. - The company acquired a 44.80% stake in Fuli Instruments, gaining control over the board, which will be included in the consolidated financial statements starting March 2024 [157]. - The company plans to establish a wholly-owned subsidiary, Nantong Nawei New Materials Co., Ltd., with an investment of CNY 100 million to enhance its production capacity and market competitiveness [184]. - The company has invested a total of RMB 30 million in the Suzhou Tianhui Microball Investment Partnership, with an investment amount of RMB 15 million reported by the end of the period [189]. Customer and Supplier Relationships - The company has established solid partnerships with numerous pharmaceutical manufacturers, research institutions, and CRO/CDMO enterprises [68]. - The company’s total revenue from the top five customers was 12,782.44 million RMB, accounting for 16.34% of annual sales, with no sales to related parties [158]. - The top five suppliers accounted for 19.66% of the total annual procurement amount, totaling 36.21 million RMB [164]. - The company has established a robust platform for in vitro diagnostic microsphere materials, focusing on high-performance raw materials for diagnostic reagent manufacturers [92].